MTOR Gene

MTOR Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MTOR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>MTOR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>[Mechanistic Target of Rapamycin](/entities/mtor)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p36.22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2475</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000164362</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>601231</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P42345</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2549 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~289 kDa</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">S6K1</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">4E-BP1</td>
<td>Translation initiation</td>
</tr>
<tr>
<td class="label">ULK1</td>
<td>Autophagy initiation</td>
</tr>
<tr>
<td class="label">TFEB</td>
<td>Lysosomal biogenesis</td>
</tr>
<tr>
<td class="label">SREBP</td>
<td>Lipid synthesis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>Allosteric mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mT

...

MTOR Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MTOR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>MTOR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>[Mechanistic Target of Rapamycin](/entities/mtor)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p36.22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2475</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000164362</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>601231</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P42345</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2549 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~289 kDa</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">S6K1</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">4E-BP1</td>
<td>Translation initiation</td>
</tr>
<tr>
<td class="label">ULK1</td>
<td>Autophagy initiation</td>
</tr>
<tr>
<td class="label">TFEB</td>
<td>Lysosomal biogenesis</td>
</tr>
<tr>
<td class="label">SREBP</td>
<td>Lipid synthesis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>Allosteric mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mTORC1/2 inhibitor</td>
</tr>
<tr>
<td class="label">Temsirolimus</td>
<td>Prodrug of rapamycin</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>mTORC1/2</td>
</tr>
<tr>
<td class="label">RAD001 (Everolimus)</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">AZD8055</td>
<td>mTORC1/2</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/adh" style="color:#ef9a9a">ADH</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-51e7234f" style="color:#ce93d8" title="Score: 0.80">APOE-Dependent Autophagy Restoration...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4198 edges</a></td>
</tr>
</table>

Introduction

[Mtor](/mechanisms/mtor-signaling-pathway) Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The MTOR gene (Mechanistic Target of Rapamycin) encodes a serine/threonine kinase that is a central regulator of cell growth, metabolism, and autophagy. In the brain, [mTOR](/proteins/mtor-protein) signaling is crucial for synaptic plasticity, protein synthesis, and autophagy. Dysregulated mTOR signaling is implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [tuberous sclerosis](https://omim.org/entry/191100).

The MTOR gene is located on chromosome 1p36.22 and encodes a 2549-amino acid protein (molecular weight ~289 kDa). It is a member of the PI3K-related kinase (PI3K-related) family and exists in two structurally and functionally distinct complexes: mTORC1 and mTORC2^{[@lipton2021]}.

Gene Information

Protein Structure and Complexes

mTORC1 (mTOR Complex 1)

mTORC1 consists of mTOR, Raptor (regulatory-associated protein of mTOR), and mLST8 (also known as GβL). It functions as a nutrient-sensitive regulator of cell growth and metabolism:

• Raptor: Scaffold protein that recruits substrates to mTORC1
• mLST8: Stabilizes the kinase domain
• PRAS40: Inhibitory subunit that blocks substrate access

mTORC2 (mTOR Complex 2)

mTORC2 consists of mTOR, Rictor (rapamycin-insensitive companion of mTOR), mLST8, and Sin1. It regulates:

• Actin cytoskeleton organization
• Cell survival through AKT activation
• Ion transport

Normal Function

mTOR is a central kinase integrating nutritional, growth factor, and energy signals:

• mTORC1 (mTOR + Raptor): Regulates protein synthesis, cell growth, autophagy
• mTORC2 (mTOR + Rictor): Regulates actin cytoskeleton, cell survival
• Protein Synthesis: Phosphorylates S6K1 and 4E-BP1
• [Autophagy](/mechanisms/autophagy-lysosomal-pathway) Inhibition: mTORC1 is the major autophagy inhibitor
• Synaptic Plasticity: Regulates [LTP](/mechanisms/long-term-potentiation) and memory consolidation
• mRNA Translation: Controls translation initiation and elongation

Upstream Regulation

mTOR receives input from multiple signaling pathways:

Downstream Targets

Molecular Mechanism in Neurodegeneration

mTOR Dysregulation in Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), mTOR signaling is profoundly dysregulated:

Amyloid-β mediated activation: Aβ oligomers activate mTORC1 through PI3K/AKT, creating a feed-forward loop where Aβ → mTOR → increased Aβ production^[@bove2020]

Tau-mediated mTOR dysregulation: Hyperphosphorylated tau disrupts TSC1/2 complex, leading to mTORC1 hyperactivation

Autophagy impairment: mTORC1 hyperactivation inhibits autophagy, leading to accumulation of damaged proteins and organelles

Synaptic dysfunction: mTOR regulates AMPA and [NMDA](/cell-types/nmda-receptor) receptor trafficking; dysregulation contributes to synaptic loss

Protein synthesis abnormalities: mTOR hyperactivation leads to abnormal synaptic protein synthesis

mTOR in Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease):

α-Synuclein accumulation: mTORC1-mediated autophagy inhibition leads to impaired clearance of [α-synuclein](/proteins/alpha-synuclein)^[@maze2019]

Dopaminergic neuron vulnerability: mTOR dysregulation in substantia nigra pars compacta

Mitochondrial dysfunction: mTOR regulates mitophagy; impairment contributes to energy failure

Neuroinflammation: mTOR signaling in microglia contributes to inflammatory responses

mTOR in ALS

In [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis):

Protein aggregation: Impaired autophagy leads to TDP-43 and other protein aggregates

Dysregulated translation: Abnormal mRNA metabolism in motor neurons

Energy metabolism: mTOR regulates cellular energetics; dysregulation contributes to metabolic crisis^[@liu2018]

mTOR in Tuberous Sclerosis Complex

[TSC](/diseases/tuberous-sclerosis) is caused by mutations in TSC1 or TSC2 genes, which normally inhibit mTORC1:

• TSC1/2 mutations: Loss of function leads to mTORC1 hyperactivation
• Cortical tubers: Abnormal neuronal migration and proliferation
• Seizures: Common manifestation due to cortical dysfunction
• mTOR inhibitors: Everolimus and sirolimus are approved treatments^[@crino2016]

Signaling Pathway

PI3K/AKT/mTOR Pathway

Autophagy Regulation

mTORC1 is the major negative regulator of autophagy:

ULK1 complex: mTORC1 phosphorylates ULK1, inhibiting autophagy initiation

Atg14L: mTORC1 regulates Beclin1-Vps34 complex

TFEB: mTORC1 phosphorylates and sequesters TFEB in cytoplasm, inhibiting lysosomal biogenesis

Expression Pattern

mTOR is ubiquitously expressed in all cell types in the brain:

• [Neurons](/cell-types/neurons) (high expression in dendritic shafts)
• [Astrocytes](/cell-types/astrocytes)
• [Oligodendrocytes](/cell-types/oligodendrocytes) [Microglia](/cell-types/microglia)

Highest expression in:

• Cerebral [cortex](/brain-regions/cortex)
• [Hippocampus](/brain-regions/hippocampus) (CA1 pyramidal neurons)
• Cerebellar Purkinje cells

Therapeutic Targeting

Approved mTOR Inhibitors

Drugs in Development for Neurodegeneration

Therapeutic Mechanisms

Autophagy induction: mTOR inhibition releases autophagy blockade, enabling clearance of toxic proteins

Neuroinflammation reduction: mTOR inhibitors reduce microglial activation

Synaptic protection: Normalization of synaptic protein synthesis

Metabolic effects: Improved cellular energetics

Clinical Considerations

• BBB penetration: Rapamycin has moderate BBB penetration
• Immunosuppression: Systemic mTOR inhibition causes immunosuppression
• Adverse effects: Hyperlipidemia, wound healing issues, stomatitis
• Temporal dynamics: Acute vs. chronic mTOR modulation may have different effects

Animal Models

Several animal models have been used to study mTOR in neurodegeneration:

• mTOR conditional knockout mice: Neuron-specific deletion shows impaired synaptic plasticity
• TSC1/2 knockout mice: Model of tuberous sclerosis with mTOR hyperactivation
• Rapamycin treatment in AD models: Improves cognitive function in APP/PS1 mice^{[@caccamo2010]}
• mTOR overexpression models: Show enhanced protein synthesis and synaptic dysfunction

Key Publications

[Lipton JO, Sahin M. The neurology of mTOR (2021)](https://doi.org/10.1016/j.neuron.2021.07.025)

[Perluigi M, et al. mTOR signaling in neurodegeneration (2022)](https://doi.org/10.1007/s12035-021-02654-w)

[Bove J, et al. mTOR hyperactivation in Alzheimer's disease (2020)](https://doi.org/10.3233/JAD-200137)

[Maze M, et al. mTOR in Parkinson's disease (2019)](https://doi.org/10.1016/j.nbd.2019.104521)

[Liu G, et al. mTOR inhibition in ALS (2018)](https://doi.org/10.1002/ana.25338)

[Crino PB. The mTOR pathway in TSC (2016)](https://doi.org/10.1002/ana.24587)

[Hoeffer CA, et al. mTOR and memory (2010)](https://doi.org/10.1038/nrn2730)

[Caccamo A, et al. Rapamycin rescues learning (2010)](https://doi.org/10.1074/jbc.M110.133488)

[Tang SJ, et al. mTOR signaling in synaptic plasticity (2014)](https://doi.org/10.1101/cshperspect.a005140)

[Hernandez D, et al. mTOR in PD and autophagy (2018)](https://doi.org/10.1002/mds.27334)

See Also

• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [AMPK Pathway](/mechanisms/ampk-signaling-pathway)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [Tuberous Sclerosis Complex](/diseases/tuberous-sclerosis)

External Links

• [NCBI Gene: MTOR](https://www.ncbi.nlm.nih.gov/gene/2475)
• [UniProt: MTOR](https://www.uniprot.org/uniprot/P42345)
• [GeneCards: MTOR](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MTOR)
• [IUPHAR: MTOR](https://www.guidetopharmacology.org/GTP-ligands.php?geneId=2017)
• [Allen Human Brain Atlas: MTOR](https://human.brain-map.org/microarray/search/show?search_term=MTOR)
• [Allen Mouse Brain Atlas: MTOR](https://mouse.brain-map.org/search/index.html?query=MTOR)
• [BrainSpan Atlas: MTOR](https://www.brainspan.org/rnaseq/search/index.html?search_term=MTOR)

Background

The study of Mtor Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Perluigi M, et al, mTOR signaling in neurodegeneration (2022)](https://doi.org/10.1007/s12035-021-02654-w)

[Lipton JO, Sahin M, The neurology of mTOR (2021)](https://doi.org/10.1016/j.neuron.2021.07.025)

[Bove J, et al, mTOR hyperactivation in Alzheimer's disease (2020)](https://doi.org/10.3233/JAD-200137)

[Maze M, et al, mTOR in Parkinson's disease (2019)](https://doi.org/10.1016/j.nbd.2019.104521)

[Liu G, et al, mTOR inhibition in ALS (2018)](https://doi.org/10.1002/ana.25338)

[Crino PB, The mTOR pathway in TSC (2016)](https://doi.org/10.1002/ana.24587)

[Takei N, et al, Brain mTOR signaling and synaptic plasticity (2008)](https://pubmed.ncbi.nlm.nih.gov/18451643/)

[Hoeffer CA, et al, mTOR and memory (2010)](https://doi.org/10.1038/nrn2730)

[Caccamo A, et al, Rapamycin rescues learning and memory deficits (2010)](https://doi.org/10.1074/jbc.M110.133488)

[Tang SJ, et al, mTOR signaling in synaptic plasticity (2014)](https://doi.org/10.1101/cshperspect.a005140)

[Swiech L, et al, mTOR in neuronal plasticity (2014)](https://doi.org/10.1038/npp.2013.207)

[Hernandez D, et al, mTOR in PD and autophagy (2018)](https://doi.org/10.1002/mds.27334)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR

Pathway Diagram

The following diagram shows the key molecular relationships involving MTOR Gene discovered through SciDEX knowledge graph analysis:

Associated Diseases

• Als — associated with

[View disease page](/diseases/als)

• ALS — associated with

[View disease page](/diseases/als)

• Alzheimer — associated with

[View disease page](/diseases/alzheimer)

• Alzheimer Disease — associated with

[View disease page](/diseases/alzheimer-disease)

• Alzheimer's disease — associated with

[View disease page](/diseases/alzheimers-disease)

• Alzheimer's Disease — associated with

[View disease page](/diseases/alzheimers-disease)

• Alzheimer'S Disease — implicated in

[View disease page](/diseases/alzheimers-disease)

• ALZHEIMER'S DISEASE — associated with

[View disease page](/diseases/alzheimers-disease)

• Amyotrophic Lateral Sclerosis — associated with

[View disease page](/diseases/amyotrophic-lateral-sclerosis)

• Dementia — causes

[View disease page](/diseases/dementia)

• DEMENTIA — associated with

[View disease page](/diseases/dementia)

• Frontotemporal dementia — implicated in

[View disease page](/diseases/frontotemporal-dementia)

• FRONTOTEMPORAL DEMENTIA — associated with

[View disease page](/diseases/frontotemporal-dementia)

• Parkinson — associated with

[View disease page](/diseases/parkinson)

• Parkinson's disease — associated with

[View disease page](/diseases/parkinsons-disease)

• PARKINSON'S DISEASE — associated with

[View disease page](/diseases/parkinsons-disease)